NCT05320835 A Setting Focus Overdose Prevention Intervention
| NCT ID | NCT05320835 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Condition | HIV Infections |
| Study Type | INTERVENTIONAL |
| Enrollment | 285 participants |
| Start Date | 2022-04-30 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 285 participants in total. It began in 2022-04-30 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).
Eligibility Criteria
Inclusion Criteria: * Current drug user (opioid use in the prior two weeks) Exclusion Criteria: * Any mental or physical health impairment that impedes ability to participate
Contact & Investigator
Carl Latkin, PhD
PRINCIPAL INVESTIGATOR
Johns Hopkins Bloomberg School of Public Health
Frequently Asked Questions
Who can join the NCT05320835 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05320835 currently recruiting?
Yes, NCT05320835 is actively recruiting participants. Contact the research team at carl.latkin@jhu.edu for enrollment information.
Where is the NCT05320835 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT05320835 clinical trial?
NCT05320835 is sponsored by Johns Hopkins Bloomberg School of Public Health. The principal investigator is Carl Latkin, PhD at Johns Hopkins Bloomberg School of Public Health. The trial plans to enroll 285 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.